Articles from Tandem Diabetes Care

Tandem Diabetes Care® (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the publication of a study, "Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level," in the American Diabetes Association’s Diabetes Care. The study, a sub-analysis from the 2IQP randomized, controlled trial, found that the Control-IQ+ automated insulin delivery (AID) system was beneficial for adults with insulin-treated type 2 diabetes, regardless of their C-peptide levels.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2021 results after the financial markets close on Wednesday, May 5, 2021. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2021 financial and operating results.